Hardi Mundl
About
Hardi Mundl is a scholar working on Cardiology and Cardiovascular Medicine, Epidemiology and Internal Medicine.
According to data from OpenAlex, Hardi Mundl has authored 30 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Cardiology and Cardiovascular Medicine, 15 papers in Epidemiology and 10 papers in Internal Medicine. Recurrent topics in Hardi Mundl's work include Acute Ischemic Stroke Management (15 papers), Atrial Fibrillation Management and Outcomes (15 papers) and Venous Thromboembolism Diagnosis and Management (10 papers). Hardi Mundl is often cited by papers focused on Acute Ischemic Stroke Management (15 papers), Atrial Fibrillation Management and Outcomes (15 papers) and Venous Thromboembolism Diagnosis and Management (10 papers). Hardi Mundl collaborates with scholars based in United States, Germany and Canada. Hardi Mundl's co-authors include Markus Abt, Anders Olsson, David Kallend, Gregory G. Schwartz, Ingar Holme, John J.V. McMurray, Christie M. Ballantyne, Lawrence A. Leiter, Jochen Brumm and Philip J. Barter and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.
In The Last Decade
Hardi Mundl
27 papers receiving 2.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hardi Mundl United States | 13 | 1.2k | 958 | 687 | 356 | 344 | 30 | 2.1k | ||
| Ye‐Xuan Cao China | 22 | 759 0.6× | 580 0.6× | 633 0.9× | 321 0.9× | 197 0.6× | 69 | 1.5k | ||
| Christian M. Madsen Denmark | 25 | 1.5k 1.3× | 842 0.9× | 695 1.0× | 316 0.9× | 420 1.2× | 50 | 2.3k | ||
| Pia Lundman Sweden | 28 | 826 0.7× | 770 0.8× | 912 1.3× | 484 1.4× | 237 0.7× | 70 | 2.5k | ||
| Yuan‐Lin Guo China | 29 | 1.8k 1.5× | 994 1.0× | 1.2k 1.7× | 534 1.5× | 428 1.2× | 156 | 3.2k | ||
| Na‐Qiong Wu China | 31 | 1.9k 1.5× | 1.1k 1.1× | 1.2k 1.8× | 572 1.6× | 483 1.4× | 192 | 3.3k | ||
| Angelo B. Cefalù Italy | 26 | 1.1k 0.9× | 896 0.9× | 864 1.3× | 370 1.0× | 384 1.1× | 129 | 2.5k | ||
| G. Kees Hovingh Netherlands | 30 | 2.1k 1.8× | 1.3k 1.3× | 1.0k 1.5× | 298 0.8× | 646 1.9× | 76 | 3.4k | ||
| Ichiro Michishita Japan | 22 | 1.1k 0.9× | 546 0.6× | 457 0.7× | 145 0.4× | 268 0.8× | 88 | 1.9k | ||
| Min‐Ji Charng Taiwan | 16 | 883 0.7× | 522 0.5× | 582 0.8× | 202 0.6× | 334 1.0× | 40 | 2.3k | ||
| Dov Gavish Israel | 26 | 1.1k 0.9× | 787 0.8× | 714 1.0× | 380 1.1× | 386 1.1× | 70 | 2.7k |
Countries citing papers authored by Hardi Mundl
Since
Specialization
Citations
This map shows the geographic impact of Hardi Mundl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hardi Mundl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hardi Mundl more than expected).
Fields of papers citing papers by Hardi Mundl
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Hardi Mundl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hardi Mundl. The network helps show where Hardi Mundl may publish in the future.
Co-authorship network of co-authors of Hardi Mundl
This figure shows the co-authorship network connecting the top 25 collaborators of Hardi Mundl. A scholar is included among the top collaborators of Hardi Mundl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hardi Mundl. Hardi Mundl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Marchis, Gian Marco De, Tolga Dittrich, Dimitrios Vlachos, et al.. (2025). Dual versus single antiplatelet therapy in patients with non-cardioembolic acute ischemic stroke and baseline MRI. European Stroke Journal. 10(3). 766–774.
2.
Chen, Chih‐Hao, Ashkan Shoamanesh, Pablo Colorado, et al.. (2025). Hemorrhagic Infarction Does Not Worsen Functional Outcomes in Noncardioembolic Ischemic Stroke: Secondary Analysis From PACIFIC-STROKE. Stroke. 56(7). 1730–1737.
3.
Eikelboom, John W., Hardi Mundl, John H. Alexander, et al.. (2024). Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials. Journal of the American College of Cardiology. 83(6). 669–678.
4.
Bhagirath, Vinai, Jia Wang, Lizhen Xu, et al.. (2024). Bleeding Risk Prediction in Patients Treated with Antithrombotic Drugs According to the Anatomic Site of Bleeding, Indication for Treatment, and Time Since Treatment Initiation. SHILAP Revista de lepidopterología. 8(1). e121–e131.
5.
Chen, Chih‐Hao, Ashkan Shoamanesh, Pablo Colorado, et al.. (2024). Hemorrhagic Transformation in Noncardioembolic Acute Ischemic Stroke: MRI Analysis From PACIFIC-STROKE. Stroke. 55(6). 1477–1488.
6.
Sarraju, Ashish, Thomas Viethen, Hardi Mundl, et al.. (2022). Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP). npj Digital Medicine. 5(1). 80–80.
7.
Bosch, Jackie, Lesly A. Pearce, Mukul Sharma, et al.. (2022). Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial. Journal of Stroke and Cerebrovascular Diseases. 31(5). 106404–106404.
8.
Parameswaran, V., Udhayvir Singh Grewal, Thomas Viethen, et al.. (2021). Validation of a pandemic-proof, decentralized cardiovascular trial: scalable design produces rapid recruitment, high engagement and protocol adherence in DeTAP (Decentralized Trial in Afib Patients). European Heart Journal. 42(Supplement_1).
9.
Ameriso, Sebastián F., Pierre Amarenco, Lesly A. Pearce, et al.. (2020). Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. Journal of Stroke and Cerebrovascular Diseases. 29(8). 104936–104936.
10.
Mikulík, Robert, Jens Eckstein, Lesly A. Pearce, et al.. (2020). Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source. Stroke. 51(7). 2139–2147.
11.
Shoamanesh, Ashkan, Robert G. Hart, Stuart J. Connolly, et al.. (2020). Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source. JAMA Neurology. 78(1). 11–11.
12.
Povsic, Thomas J., E. Magnus Ohman, Matthew T. Roe, et al.. (2019). P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. JAMA Cardiology. 4(7). 680–680.
13.
Uchiyama, Shinichiro, Ḱazunori Toyoda, Kazuo Kitagawa, et al.. (2019). Branch atheromatous disease diagnosed as embolic stroke of undetermined source: A sub-analysis of NAVIGATE ESUS. International Journal of Stroke. 14(9). 915–922.
14.
Georgi, Benjamin, Johanna Mielke, Mark Chaffin, et al.. (2019). Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI. Stroke. 50(11). 3004–3012.
15.
Ntaios, George, Lesly A. Pearce, Elena Meseguer, et al.. (2019). Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source. Stroke. 50(11). 3184–3190.
16.
Hart, Robert G., et al.. (2018). Rivaroxaban for stroke prevention after embolic stroke of undetermined source. Journal of Vascular Surgery Venous and Lymphatic Disorders. 7(1). 147–147.
17.
Povsic, Thomas J., Matthew T. Roe, E. Magnus Ohman, et al.. (2016). A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. American Heart Journal. 174. 120–128.
18.
Veltkamp, Roland, Antoni Dávalos, Danilo Toni, et al.. (2015). Navigate ESUS: Multicenter, randomized double-blind, phase III study of prevention of recurrent stroke and systemic embolism in patients with recent embolic stroke of undetermined source. International Journal of Stroke. 10. 431–432.
19.
Schwartz, Gregory G., Markus Abt, Weihang Bao, et al.. (2015). Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins. Journal of the American College of Cardiology. 65(21). 2267–2275.
20.
Schwartz, Gregory G., Anders Olsson, Markus Abt, et al.. (2012). Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine. 367(22). 2089–2099.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ye‐Xuan Cao Breakdown of academic impact, for papers by Christian M. Madsen Breakdown of academic impact, for papers by Pia Lundman Breakdown of academic impact, for papers by Yuan‐Lin Guo Breakdown of academic impact, for papers by Na‐Qiong Wu Breakdown of academic impact, for papers by Angelo B. Cefalù Breakdown of academic impact, for papers by G. Kees Hovingh Breakdown of academic impact, for papers by Ichiro Michishita Breakdown of academic impact, for papers by Min‐Ji Charng Breakdown of academic impact, for papers by Dov Gavish